Brilinta: new oral antiplatelet agent for prevention of CV events after ACSDrug intended for patients managed medically or with percutaneous coronary intervention and/or coronary artery bypass graft surgery. AIM-HIGH falls shortNIH puts an early end to its trial of combination cholesterol therapy Letters: Discussing Dabigatran I would like to comment on a few points discussed in the article on dabigatran (Medication Forum, April/May 2011). The pressure’s on to treat resistant hypertension Causes of this common problem in primary care may include overlooked comorbidities or unrelated medications A new view of women’s cardiovascular risks Updated guidelines consider long-term risk with wider focus beyond coronary artery disease CABG adds little to ischemic heart failure treatment Sensitive troponin assay improves MI detection Value of adiposity measures such as BMI questioned Managing heart failure on the front lines of care Family physicians are key players in helping patients to follow treatment plans and avoid hospitalization Radial artery access is rad for PCI First Previous 65 66 67 68 69 Next Last
